Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 7682 results

  1. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

      Status ...

    Technology appraisal guidance
    Topic selection

  3. IgPro20 for treating dermatomyositis TS ID 12014

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    Medical technologies guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for MTG12

  9. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

    Technology appraisal guidance
    Topic selection

  10. The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)

    Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

    Medical technologies guidance
    Last updated
    25 March 2019
    View recommendations

    Sections for MTG17

  11. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  12. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Targeted Muscle Reinnervation for refractory pain after limb amputation

    In development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    In development

  14. Transcatheter aortic valve implantation for native aortic valve regurgitation

    In development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    In development

  15. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development